Pretransplant HbA1c Is a Useful Predictor for the Development of New-Onset Diabetes in Renal Transplant Recipients Receiving No or Low-Dose Erythropoietin
Table 1
Comparison of patients who developed NODATa (NODAT+) to those who did not (NODAT−).
Variable
NODAT+ ( = 17)
NODAT− ( = 102)
value
Recipient age [y]
47.5 (10.5)
38.7 (11.7)
<0.005
Recipient gender (M/F)
(15/2)
(64/38)
0.05
Donor age [y]
53.4 (7.9)
55.6 (10.2)
0.38
Donor gender (M/F)
(4/13)
(36/66)
0.42
Fasting plasma glucose [mg/dL]
82.9 (6.9)
80.1 (9.0)
0.22
HbA1c [%]
5.2 (0.45)
4.9 (0.45)
<0.05
Hemoglobin [g/L]
10.6 (2.4)
10.4 (1.8)
0.60
EPOb (none/low-dosec/high-dosed)
(1/11/4)
(15/59/25)
0.74
Cause of chronic renal failure
0.50
Glomerulonephritis
13 (76%)
62 (61%)
Polycystic kidney disease
0 (0%)
4 (4%)
Hypertension/nephrosclerosis
1 (6%)
4 (4%)
Other/unknown
3 (18%)
32 (31%)
Pretransplant BMIe
21.1 (2.6)
21.2 (3.1)
0.95
Dialysis period [mo]
24 (0–171)
15 (0–198)
0.23
Hepatitis C positive
2 (12%)
1 (1%)
0.05
ABO incompatible
3 (18%)
15 (15%)
0.72
aNew-onset diabetes after transplantation.
bErythropoietin.
c0 < EPO ≤ 6,000 IU/week.
dEPO > 6,000 IU/week.
eBody mass index [kg/m2].
